Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Impact · against what's priced in

Replimune shares are likely to rise as 3-year landmark overall survival data from the IGNYTE trial demonstrates high durability (83.5% of responders alive) in a treatment-resistant melanoma population. This provides strong clinical validation for RP1 as it undergoes FDA BLA review.

REPL+0.70

No priced-in read yet